CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...
A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...
CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
Decades ago, Amber Salzman remembers feeling like there was nothing she could do to help her cousin-in-law with a progressive ...
At meeting on human embryo editing, CRISPR pioneer says science is a long way from knowing if germline DNA can be safely ...
2don MSN
We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
Many clinical trials aren’t able to even move past the recruitment and enrollment stage. According to Deloitte, a “study on ...
CRISPR and Vertex have obtained approval for clinical trial applications for several countries outside the US for beta-thalassemia and SCD. They said they are on track to begin a phase 1/2 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback